Jan 1, 2025, 14:24 | Blog

Chris De Savi: FDA Novel Drug approvals in 2024

Chris De Savi, Senior Vice President and Head of Drug Discovery at Kymera Therapeutics and…

Jan 1, 2025, 14:21 | Insight

Hung Trinh: Groundbreaking Stanford University cancer treatment received FDA designation

Hung Trinh, Senior Director of Business Development at OBiO Tech, shared a post on LinkedIn:…

Dec 31, 2024, 09:49 | Insight

Mark Lythgoe: Subcutaneous nivolumab approved by FDA Oncology across all indications

Mark Lythgoe, Clinical Research Fellow in Medical Oncology at Imperial College London, shared on X:…

Dec 30, 2024, 12:39 | Insight

When Diversity Goals Meet Multiregional Trials by Gautam Mehta et al. - FDA Oncology

FDA Oncology shared a post on X about a recent paper by Gautam Mehta et…

Dec 30, 2024, 00:53 | Science

Marco Donia about the FDA approved nivolumab across solid tumors

Marco Donia, Senior Consultant at the University of Copenhagen Herlev Hospital, shared a recent article…

Dec 29, 2024, 13:44 | Insight

Stanford’s Pediatric Cancer Treatment Received FDA RMAT Designation

Stanford Medicine’s new treatment for deadly pediatric brain and spinal cord cancers has been granted…

Dec 29, 2024, 13:27 | Blog

Adam Lenkowsky: Celebrating the FDA approval of our new subcutaneous immunotherapy for patients with certain cancers

Adam Lenkowsky, Executive Vice President, Chief Commercialization Officer at Bristol Myers Squibb, reshared a post…

Dec 29, 2024, 10:19 | Insight

Pashtoon Kasi: All about efficiency

Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, Orange County, shared…

Dec 29, 2024, 10:07 | Blog

Oncology Brothers: 14 new drugs/indications in Lung Cancer by FDA in 2024

Oncology Brothers posted on X: "2024 approvals: Summary of 14 new drugs/indications in Lung Cancer…

Dec 28, 2024, 18:13 | Blog

Ahmed Magdy Rabea: A new delivery method for a powerful weapon against cancer

Ahmed Magdy Rabea, Assistant Professor of Medical Oncology and Hematology at the National Cancer Institute,…

Dec 28, 2024, 18:13 | Insight

Additional findings from the CodeBreak 200 trial

OHC - Oncology Hematology Care shared a post on LinkedIn: “OHC medical oncologist and hematologist…

Dec 28, 2024, 18:09 | Drugs

Rami Manochakian: FDA approved subcutaneous Nivolumab for Solid Tumors

Rami Manochakian, Thoracic medical oncologist at Mayo Clinic, shared a post on X: "U.S FDA…

Dec 28, 2024, 15:55 | Science

Chris Boerner: The FDA approved our new subcutaneous immunotherapy treatment

Chris Boerner, Board Chair and Chief Executive Officer at Bristol Myers Squibb, posted on LinkedIn:…

Dec 28, 2024, 13:45 | Insight

FDA Approved Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; subcutaneous nivolumab) for subcutaneous injection for…

Dec 28, 2024, 13:43 | Insight

TEVIMBRA Received FDA Approval as First-Line Therapy for Gastric and GEJ Cancers in Combination with Chemotherapy

The additional indication for first-line treatment of gastric and gastroesophageal junction cancers is supported by…

Dec 28, 2024, 11:40 | Science

Elvina Almuradova: Tislelizumab-jsgr with chemotherapy as a first-line treatment for metastatic HER2-negative GEJ adenocarcinoma

Elvina Almuradova, Associate Professor at Medicana Health Group, posted on LinkedIn: "The FDA has approved…

Dec 28, 2024, 11:14 | Science

Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial

Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on X: "Tislelizumab gets…

Dec 28, 2024, 10:25 | Blog

Joe Lennerz: A pivotal moment in the ongoing debate over FDA’s regulation of LDTs

Joe Lennerz, Chief Scientific Officer at Boston Gene, shared a post on LinkedIn: "The U.S.…

Dec 27, 2024, 17:06 | Science

Wafik S. El-Deiry: Pitfalls and perils from FDA-approved germ-line cancer predisposition tests

Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, posted…

Dec 27, 2024, 15:44 | Blog

Giuseppe Caruso: 2024 - A Break through Year in Gynecologic Oncology

Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post…

Dec 27, 2024, 14:24 | Science

Oncology Brothers: 6 new drugs/indications in GI Malignancies by FDA in 2024

Oncology Brothers posted on X: "2024 approvals: Summary of 6 new drugs/indications in GI Malignancies…

Dec 27, 2024, 14:00 | Insight

Kimryn Rathmell: The year in cancer - 24 advances in 2024

National Cancer Institute (NCI) shared a post on LinkedIn: "By Kimryn Rathmell, Director, National Cancer…

Dec 25, 2024, 21:43 | Blog

Rohit Gosain: Summary of 12 new indications in heme malignancies FDA in 2024

Rohit Gosain, Co-Host of Podcast Oncology Brothers, shared a post on LinkedIn: "2024 approvals: Summary…

Dec 25, 2024, 16:25 | Blog

Rohit Gosain: Summary of 8 new drugs/indications in Breast Cancer and Gynae Oncology by FDA

Rohit Gosain, Co-Host of Podcast Oncology Brothers, shared a post on LinkedIn: "2024 approvals: Summary of…

Dec 25, 2024, 03:51 | Insight

Maria Babak: Critical advancement in the treatment of mCSCC and laCSCC

Maria Babak, Head of The Babak Lab and an Assistant Professor at the City University…

Dec 24, 2024, 07:26 | Drugs

FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment

Nitolinib, developed by Hetero under a sublicense from the Medicines Patent Pool (MPP), is the…

Dec 24, 2024, 00:40 | Blog

Chris Boshoff: Targeted treatment regimen for mCRC with a BRAF V600E mutation

Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared a post on…

Dec 22, 2024, 07:55 | Science

Ahmed Kotb: The Rapidly Evolving AML Treatment Landscape

Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company…

Dec 22, 2024, 06:53 | Insight

FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer

On December 20, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to…

Dec 22, 2024, 06:43 | Insight

invIOs to present progress across oncology pipeline during JP Morgan Week 2025

invIOs GmbH ("invIOs"), a privately held biotechnology company developing novel therapies for cancer, will be…

Dec 21, 2024, 22:26 | Blog

Anas Younes: Transforming outcomes for people living with Blood Cancer

Anas Younes, Senior VP, Global Head of Hematology (Early and Late Stage), Oncology R&D at…

Dec 21, 2024, 08:48 | Science

Oncology Brothers: Another ALK inhibitor gets FDA approval

Oncology Brothers posted on X: "Another ALK inhibitor (ensartinib) gets FDA approval eXalt3 study: 1L,…

Dec 21, 2024, 05:01 | Insight

FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to dostarlimab for the treatment of patients…

Dec 20, 2024, 16:10 | Blog

Boris Pasche: FDA has approved the TheraBionic P1 device for advanced hepatocellular carcinoma

Boris Pasche, President and CEO of the Karmanos Cancer Institute, shared a post on LinkedIn:…

Dec 20, 2024, 06:58 | Science

Stephen V Liu: Will have to wait a bit longer for subcutaneous amivantamab

Stephen V Liu, Associate Professor of Medicine at Georgetown University, posted on X: "Will have…

Dec 19, 2024, 11:58 | Insight

Aakash Desai: Exciting news for extensive-stage small-cell lung cancer

Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn: “Exciting news…

Dec 19, 2024, 02:11 | Blog

An upcoming FDA-AACR workshop on DPD deficiency testing

AACR (American Association for Cancer Research) shared a post on X: “Considerations for dihydropyrimidine dehydrogenase…

Dec 18, 2024, 18:34 | Blog

Razelle Kurzrock: Pleasure to give talk for Cancer Precision Medicine Commons

Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…

Dec 17, 2024, 16:47 | Science

Dostarlimab Plus Chemo Earned Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended…

Dec 17, 2024, 01:10 | Science

Hung Trinh: Optimizing the post-CAR T monitoring period in recipients of Axi-cel, Tisa-cel, and Liso-cel by Nausheen Ahmed et al.

A recent paper by Nausheen Ahmed, Medical Director of BMT Survivorship Program at The University…

Dec 16, 2024, 11:37 | Science

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

On December 13, 2024, the FDA approved cosibelimab-ipdl, a PD-L1 blocking antibody, for adults with…

Dec 14, 2024, 13:53 | Blog

Mel Mann: Helping others have fact-based knowledge of clinical trials and access to them

Mel Mann, Patient Advocate at Health Equity, Clinical Trials, Marrow Donation, shared a post on LinkedIn: "Honored to…

Dec 12, 2024, 13:14 | Blog

Razelle Kurzrock: Targeting NRg1 fusions

Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…

Dec 11, 2024, 19:39 | Blog

SER-155 has received Breakthrough Therapy Designation from the FDA - Seres Therapeutics

Seres Therapeutics shared a post on LinkedIn: "Today we're thrilled to announce that our lead live…

Dec 11, 2024, 17:56 | Insight

Aakash Desai: A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments

Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn: “A Year…

Dec 11, 2024, 14:59 | Insight

Immunovia Announced Major Milestone in Early-Stage Pancreatic Cancer Detection

Immunovia, a leading company in pancreatic cancer diagnostics, has announced a major milestone in the…

Dec 6, 2024, 12:43 | Blog

FDA approves durvalumab for limited-stage small cell lung cancer

On December 4, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca)…

Dec 5, 2024, 11:01 | Insight

FDA Grants Accelerated Approval to Zenocutuzumab-zbco for NSCLC and Pancreatic Adenocarcinoma

On December 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval for…

Dec 4, 2024, 13:00 | Insight

Zhaohui Su: Embracing Real-World Data to Power Rare Cancer Research

"The study of cancer has evolved over the last two decades, driven primarily by genomic…

Dec 4, 2024, 09:54 | Positive

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Starting on August 26, in honor of Women’s Equality Day in the United States, which…

Dec 4, 2024, 06:56 | Insight

Amy K. O’Sullivan: Challenges and Opportunities in Studying Rare Cancers

"In oncology, the shift to biomarker-defined subtypes has important implications for drug development and patient…

Dec 3, 2024, 15:29 | Insight

Nicholas Robert: Community Oncology Is Driving the Future of Cancer Research

"Precision medicine and targeted therapies have transformed the treatment of cancer for millions of patients…

Dec 1, 2024, 11:07 | Blog

FDA approved Zanidatamab to treat Advanced Metastatic Biliary Tract Cancers - Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer shared a post on LinkedIn: "The FDA has approved the drug…

Nov 30, 2024, 15:27 | Insight

Obe-cel CAR T Therapy Achieves High Response Rates in R/R B-cell ALL: FELIX Trial Results

Trial results supported recent FDA approval for patients with relapsed/refractory disease Patients with relapsed or…

Nov 29, 2024, 09:09 | Blog

Robert F. Kennedy Jr welcomes Marty Makary as a nominee commissioner for FDA

Robert F. Kennedy Jr, The United States Secretary of Health and Human Services, shared on…

Nov 28, 2024, 11:33 | Blog

Moffitt Cancer Center was named the world’s only Delcath Center of Excellence for work in percutaneous hepatic perfusion

Moffitt Cancer Center posted on X: "Moffitt was named the world’s only Delcath Center of…

Nov 27, 2024, 17:51 | Drugs

FDA Approves Oral Liquid Imatinib for Leukemia and Other Cancer Treatments

The FDA has approved the first oral liquid formulation of imatinib (Imkeldi) for treating certain…

Nov 26, 2024, 15:41 | Drugs

FDA approved a therapy for relapsed or refractory acute leukemia

Florida Cancer Specialists and Research Institute shared a post on LinkedIn: “On November 15, 2024,…

Nov 24, 2024, 18:03 | Blog

Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer

Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on X: "FDA approves…

Nov 21, 2024, 16:49 | Blog

Vivek Subbiah: Incredible Panel Discussion at the Target Cancer Foundation Think Tank

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…

Nov 21, 2024, 09:55 | Blog

New Hope for Mantle Cell Lymphoma Patients - The Babak Lab

The Babak Lab shared a post on LinkedIn: “FDA Approval Alert: New Hope for Mantle…

Nov 20, 2024, 12:34 | Dialogues

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

In a career that spans nearly half a century in oncology, including 25 years at…

Nov 20, 2024, 11:30 | Insight

Flora Xydaki: Biomarkers in Oncology - Transforming Cancer Diagnosis and Treatment

Flora Xydaki, Project Associate at BTHT, shared a post on LinkedIn: "Biomarkers in Oncology: Transforming Cancer…

Nov 16, 2024, 11:59 | Dialogues

OncoDaily: France Bureau // vol. 4

In this week’s update, we cover key developments from the 56th SIOP Congress, including the…

Nov 14, 2024, 15:58 | Insight

Iván R. González: Warning on Sotorasib Treatment for Advanced Lung Cancer

Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared on X:…

Nov 13, 2024, 10:47 | Blog

FDA approves obecabtagene autoleucel for relapsed or refractory B-cell precursor ALL

On November 8, 2024, the Food and Drug Administration approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.),…

Nov 12, 2024, 19:26 | Blog

Jim Palma: Think Tank on Advancing Precision Medicine in Rare Cancers

Jim Palma, Chief Executive Officer at TargetCancer Foundation, shared a post on LinkedIn: "Very hard…

Nov 11, 2024, 15:46 | Blog

Tanja Obradovic: New treatment option for patients with low PDL-1 expression in head and neck cancers

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…

Nov 10, 2024, 01:23 | Blog

Daniel O'Day: Gilead Sciences announces third quarter financial results

Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences and Board Member of PhRMA and…

Nov 9, 2024, 14:35 | Drugs

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

The FDA has broadened its approval of methotrexate (Jylamvo) to include the treatment of pediatric…

Nov 7, 2024, 15:45 | Insight

Four new drugs approved by the FDA in October summarized by Samuel Hume

Samuel Hume, Scientist at the University of Oxford, shared a post on X: “The FDA…

Nov 5, 2024, 14:59 | Blog

FDA Approval for Advanced Gastric Cancer Treatment: A New Option for Patients - The Babak Lab

The Babak Lab posted on LinkedIn: "FDA Approval for Advanced Gastric Cancer Treatment: A New…

Nov 5, 2024, 05:47 | Opinion

Kamala Harris vs Donald Trump on Cancer: From Cancer Moonshot to Right to Act, Funding, Research and Future

Cancer remains one of the most pressing health challenges of our time, affecting millions of…

Nov 4, 2024, 09:03 | Insight

Dr. Richard Pazdur: 25 Years of Transforming Oncology Drug Development at the FDA

In a career that spans nearly half a century in oncology, including 25 years at…

Nov 2, 2024, 17:37 | Blog

How to Foster the Next Innovation in Oncology Clinical Development and Medical Affairs Strategy

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post by…

Nov 2, 2024, 09:27 | Blog

FDA Grants Fast Track Designation to Cothera Bioscience's PC-002

On October 23th the U.S. Food and Drug Administration (FDA) has granted Fast Track designation…

Oct 31, 2024, 08:27 | Drugs

FDA grants accelerated approval to asciminib for newly diagnosed CML

On October 29, 2024, the FDA granted accelerated approval for asciminib (Scemblix, Novartis AG) to…

Oct 29, 2024, 21:00 | Positive

Steven O'Day: At the Forefront of Immunotherapy

Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…

Oct 28, 2024, 14:26 | Insight

Faran Polani: Inspiring day at the FDA White Oak campus

Faran Polani, Hematology and Oncology Fellow at Inova Schar Cancer Institute, shared on X: “Incredibly…

Oct 28, 2024, 08:58 | Insight

Five articles suggested by Yüksel Ürün

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey.…

Oct 26, 2024, 15:59 | Insight

Jean-Charles Soria: Key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs

Jean-Charles Soria, Senior Vice President and Oncology Therapeutic Area Head at Amgen, shared a post…

Oct 26, 2024, 10:04 | Blog

Celebrating Penny’s inspiring journey and dedication to research excellence at Sarah Cannon Research Institute

Sarah Cannon Research Institute shared a post on LinkedIn: "We are excited to share the latest…

Oct 24, 2024, 10:40 | Blog

Gevorg Tamamyan: Honored to interview the Director of the FDA's Oncology Center of Excellence, Richard Pazdur

Gevorg Tamamyan shared on LinkedIn: "This year, Dr. Pazdur celebrates his 25th anniversary at the…

Oct 23, 2024, 15:44 | Drugs

FDA approves Novocure’s treatment for mNSCLC

The FDA has granted approval for Novocure's Optune Lua as a treatment option for metastatic…

Oct 23, 2024, 14:12 | Insight

Rahul Gosain: The FDA approval of Tarlatama for SCLC with Misty Shields

Rahul Gosain, Con- Host of the Oncology Brothers podcast, shared on LinkedIn: “LungCancer: Here we…

Oct 22, 2024, 16:31 | Blog

The biology and the role of biomarkers in SCLC - LUNGevity Foundation

LUNGevity Foundation shared a post on X: ''Join us for a Facebook Live on 11/1…

Oct 19, 2024, 15:57 | Insight

FDA Approves Tumor Treating Fields for Advanced NSCLC: Insights from the LUNAR Trial

The FDA has approved tumor treating fields (TTFields; Optune Lua) in combination with docetaxel or…

Oct 19, 2024, 02:16 | Blog

Real honor to meet Dr. Pazdur at AACR Annual Meeting

Wafik S. El-Deiry shared a post on X: "Real honor to meet Dr. Pazdur after…

Oct 18, 2024, 14:02 | Drugs

The CityU iGEM Team is Back in 2024 - The Babak Lab

The Babak Lab shared a post on LinkedIn: "The CityU iGEM Team is Back in 2024!…

Oct 17, 2024, 14:28 | Blog

Rahul Gosain: The FDA approval of Axatilimab and latest advancements in GVHD with Shernan Holtan

Rahul Gosain posted on LinkedIn: "Hematology: Here Rohit Gosain and I the FDA approval of Axatilimab…

Oct 16, 2024, 14:49 | Blog

Oncology Accelerated Approval Confirmatory Trials - FDA

FDA posted on LinkedIn about recent paper by Gautam Mehta and Richard Pazdur, titled "Oncology Accelerated Approval…

Oct 15, 2024, 21:29 | Insight

The 13th Annual Winship Gastrointestinal Cancer Symposium

The 13th Annual Winship Gastrointestinal Cancer Symposium took place on October 12, 2024, at the…

Oct 15, 2024, 18:54 | Blog

Shahrin Ahmed on combination therapy for Triple Negative Breast Cancer treatment

Shahrin Ahmed, Medical Specialist Oncology, Canadian Cancer Society, shared a post on X: "Triple-negative breast…

Oct 13, 2024, 05:49 | Blog

Inavolisib now FDA approved based off INAVO120 - Oncology Brothers

Oncology Brothers shared on X: "Inavolisib now FDA approved based off INAVO120: Ph III, Inavolisib…

Oct 12, 2024, 10:30 | Insight

FDA Approves Inavolisib with Palbociclib and Fulvestrant for Advanced Breast Cancer

On October 10, 2024, the FDA approved inavolisib (Itovebi, Genentech, Inc.) in combination with palbociclib…

Oct 9, 2024, 12:05 | Blog

Janet Woodcock has joined the Board of Directors of Every Cure

Janet Woodcock recently joined the Every Cure Board of Directors, focused on "rediscovering" old drugs.…

Oct 8, 2024, 11:35 | Insight

Pathways of drug development in Oncology specifically looking into time and nature of initial FDA approval, summarised by Tanja Obradovic

Tanja Obradovic shared a post on LinkedIn: "Insightful article just published by authors from National Pharmaceutical…

Oct 5, 2024, 08:59 | Insight

Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million

Palvella Therapeutics shared on LinkedIn: “Today, we announced Palvella is the recipient of an FDA…

Oct 5, 2024, 08:24 | Insight

Tanja Obradovic: New Treatment for NSCLC Patients Targeting cMet Over-Expression

Tanja Obradovic shared a post on LinkedIn: "Novel antibody-drug conjugate (ADC) may be coming for…

Oct 4, 2024, 17:28 | Blog

Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Raffaele Colombo shared a post on X: "sBLA for trastuzumab deruxtecan (T-DXd) has been accepted…